PharmacoEconomics - Modern pharmacoeconomics and pharmacoepidemiology (E-Journal) / ФАРМАКОЭКОНОМИКА. Современная фармакоэкономика и фармакоэпидемиология
Not a member yet
430 research outputs found
Sort by
ЭКОЛОГО-ЭКОНОМИЧЕСКИЕ ПРОБЛЕМЫ ТЕХНОГЕННОГО ВОЗДЕЙСТВИЯ ЗАГРЯЗНЕНИЯ НА ЗАБОЛЕВАЕМОСТЬ НАСЕЛЕНИЯ
Get PDFIn article, it is noticed that the situation which has developed in Russia brightly illustrates interdependence of system manufacture – a society – environment. Infringement of one of components conducts to infringement of functioning of all system. At the moment there are some positions of principle concerning decision-making on maintenance of quality of environmentIn article, it is noticed that the situation which has developed in Russia brightly illustrates interdependence of system manufacture – a society – environment. Infringement of one of components conducts to infringement of functioning of all system. At the moment there are some positions of principle concerning decision-making on maintenance of quality of environment
VII КОНГРЕСС С МЕЖДУНАРОДНЫМ УЧАСТИЕМ «РАЗВИТИЕ ФАРМАКОЭКОНОМИКИ И ФАРМАКОЭПИДЕМИОЛОГИИ В РОССИЙСКОЙ ФЕДЕРАЦИИ»
Get PDFVII CONGRESS WITH INTERNATIONAL PARTICIPATION «DEVELOPMENT OF PHARMACOECONOMICS AND PHARMACOEPIDEMIOLOGY IN RUSSIAN FEDERATION»VII КОНГРЕСС С МЕЖДУНАРОДНЫМ УЧАСТИЕМ «РАЗВИТИЕ ФАРМАКОЭКОНОМИКИ И ФАРМАКОЭПИДЕМИОЛОГИИ В РОССИЙСКОЙ ФЕДЕРАЦИИ
Фармакоэкономический анализ использования лираглутида в составе комбинированной терапии в лечении сахарного диабета 2-го типа
No full textСистематический обзор литературы о клинической эффективности и безопасности алоглиптина в сравнении с вилдаглиптином, линаглиптином, саксаглиптином и ситаглиптином у взрослых пациентов с сахарным диабетом 2-го типа
Get PDFType 2 diabetes mellitus (T2DM) is one the socially important diseases in the Russian Federation (RF). Dipeptidyl peptidase-4 (DPP-4) inhibitors alogliptin, vildagliptin, linagliptin, saxagliptin and sitagliptin are registered in the RF and included in both russian and international modern guidelines on T2DM.Objective: to conduct a systematical review on clinical efficacy and safety of alogliptin in comparison with other DPP-4 inhibitors in adults with T2DM.Methods. We performed a search on efficacy and safety of alogliptin compared with vildagliptin, linagliptin, saxagliptin and sitagliptin in two electronic databases: Cochrane library and Medline up to June 15th, 2015. We also searched reference lists of the relevant articles. Methodological quality of five included articles was assessed.Results. Patients on alogliptin plus metformin achieved HbA1c <7% more frequently than those treated with saxagliptin plus metformin: odds ratio (OR) 6.41, 95% confidence interval (CI) (3.15; 11.98) vs. 2.17, 95% CI (1.56; 2.95). Indirect comparison of alogliptin vs. saxagliptin or sitagliptin is not appropriate due to the differences in age and prior cardiovascular diseases severity in patients with T2DM, included in randomized controlled trials (RCT) EXAMINE, SAVOR-TIMI 53 and TECOS.Conclusion. There were no differences in efficacy in T2DM between alogliptin and other DPP-4 inhibitors, apart from in patients on alogliptin plus metformin who achieved HbA1c <7% more frequently than those treated with saxagliptin plus metformin. Indirect comparison of safety of alogliptin vs. saxagliptin or sitagliptin is not appropriate due to the differences in population of T2DM patients included in relevant RCTs; indirect comparison of safety alogliptin vs. vildagliptin or linagliptin is impossible due to the absence of the evidence base
Оценка безопасности лекарственной терапии в клинической практике Костылева М.Н.1,2, Белоусов Ю.Б.2, Грацианская А.Н.1,2,
Get PDFthe present review is devoted to an actual problem of safety of pharmacotherapy in clinical practice; the particular attention is paid to the state of this problem in pediatrics. Information about pharmacovigilance is proposed; criteria of definition, methods of collecting (their advantages and limitations), account and analysis of the adverse reactions of drugs in post-marketing period are described. The off label use of drugs in children and a role of clinical pharmacologist in the adverse reactions of drugs monitoring in a hospital is discussed.настоящий обзор посвящен актуальной проблеме безопасности фармакотерапии в клинической практике, отдельное внимание уделено состоянию проблемы в педиатрии. Предлагаются сведения о фармаконадзоре: описаны критерии определения, методы сбора (их преимущества и недостатки), учета и анализа нежелательных явлений лекарств на пострегистрационном этапе. Обсуждается проблема off label назначений лекарств у детей и роль врача-клинического фармаколога в организации мониторинга нежелательных явлений в условиях стационара
Анализ методологических особенностей исследований по изучению социально-экономического бремени заболеваний в РФ в рамках разработки стандартной методики анализа стоимости болезни с целью ее использования в оценке технологий здравоохранения
Get PDFthe concept of the relations between public health and national economy has appeared long time ago, but the development of quantitative methods started only in the middle of the XXth century. Until now there are no uninamioulsly accepted methods and approaches for this type of research. The cost of illness method (assessment of social and economic burden of disease) is one of the most widely used. Our objective was to analyze the methodologic characteristics of researches on the cost of illness in Russia for the development of the standard methodology on evaluation of the social and economic burden related to cancers to be used further for the health technology assessment. Materials and methods. Based on the results of studying foreign and national guidelines and publications devoted to the methodological issues of the cost of illness methods, we worked out the criteria list for analysis of the methodological characteristics of this type of research. Further the developed criteria list was used to study the publications on the results of cost of illness studies in Russia. Results. In total we have analyzed 6 publications on cost of illness related to cancers and 10 publications on assessement of burden related to other diseases. The analysis was considerably hampered by the insufficient description of used methods in the majority of publications. Nethertheless we have discovered major discrepancies in the choice of methods and approaches to the assessment of the disease burden, which makes impossible comparison or use of their results for the health technology assessment. Conclusions. The undertaken analysis highlightened the need for development of standardised methods as well as standardised reporting, which would allow use of research results for health technology assessment and decision making on the financing and health care management.
ФАРМАКОЭКОНОМИЧЕСКОЕ ИССЛЕДОВАНИЕ ЛЕЧЕНИЯ ПЕРВИЧНОЙ ОТКРЫТОУГОЛЬНОЙ ГЛАУКОМЫ ПРЕПАРАТАМИ ИНГИБИТОРОВ КАРБОАНГИДРАЗЫ
No full textPharmacoeconomic study of treatment primary open-angle glaucoma with carbonic anhydrise inhibitors by mean of costefficacy and budget impact analysis. Results have shown, that Azopt has benefits compare with Dorzopt and Trusopt from cost-efficacy perspective and can be claimed dominant. Futhermore Azopt in comparison with Trusopt provides cost-saving and advantage in terms of budget impact analysis.Проведено фармакоэкономическое исследование лечения первичной открытоугольной глаукомы лекарст венными препаратами ингибиторов карбоангидразы с использованием методов анализа «влияния на бюджет» и анализа «затраты-эффективность». Результаты показали, что препарат Азопт обладает преимуществом над препаратами Дорзопт и Трусопт с позиции анализа «затраты-эффективность» и относится к группе доминантных ЛС. В сравнении с препаратом Трусопт, Азопт также предоставляет экономию денежных средств, демонстрируя предпочтительность, с точки зрения анализа «влияния на бюджет»
VI КОНГРЕСС С МЕЖДУНАРОДНЫМ УЧАСТИЕМ «РАЗВИТИЕ ФАРМАКОЭКОНОМИКИ И ФАРМАКОЭПИДЕМИОЛОГИИ В РОССИЙСКОЙ ФЕДЕРАЦИИ»
Get PDFVI congress with international participation «Development of pharmacoeconomicsand pharmacoepidemiology in Russian Federation», 28-29 of February, 2012, Krasnodar28-29 февраля, VI конгресс с международным участием «Развитие фармакоэкономики и фармакоэпидемиологии в Российской Федерации», г. Краснода
ФАРМАКОЭКОНОМИЧЕСКИЙ АНАЛИЗ НЕЙРОПРОТЕКТИВНЫХ ЛЕКАРСТВЕННЫХ СРЕДСТВ В ЛЕЧЕНИИ ОСТРОГО НАРУШЕНИЯ МОЗГОВ ОГО КРОВООБРАЩЕНИЯ
No full textBased on meta-analysis dates found, that the effectiveness of neuroprotective drugs and placebo are not differences or has not statistically significant relative placebo. The cost minimization analysis showed that only Cytoflavin and Tserakson, by reducing the time of hospital treatment, reduce the cost as compared to placebo at 22311 RUB and 21345 RUB, respectively. Cost effectiveness analysis, based on the clinical practice in Russia. It is shown, that when survival used as a criterion for effectivenessevaluation, Cytoflavin with CER175003 RUB has the advantage.It was determined that the preferred scheme of treatment of acute ischemic drug is Cytoflavin therapy from the position direct costs reducing and have fewer CER while preserving the patient's life.В рамках данного фармакоэкономического исследования было проведено сравнение применения плацебо и таких нейропротективных ЛС, как Цитофлавин, Актовегин, Глиатилин, Мексидол, Цераксон и Церебролизин в лечении ОНМК. В зависимости от обнаруженных данных об эффективности применения данной группы препаратов, ФЭК-анализ проводился с учетом двух сценариев – «минимизация затрат» и «затраты-эффективность». В ходе анализа «минимизация затрат» было установлено фармакоэкономическое преимущество применения ЛС Цитофлавин и Це-раксон в фармакотерапии ОНМК, обусловленное снижением суммы прямых затрат на 22 311 руб. и 21 345 руб. соответственно. На следующем этапе исследования, в рамках анализа «затраты-эффективность», было подтверждено преимущество схемы лечения, включающей ЛС Цитофлавин, так как данная схема лечения потребует наименьших затрат на сохранение жизни пациент